C2i Genomics, AstraZeneca to collaborate on MRD test for clinical R&D

Algen Biotechnologies, AstraZeneca form AI drug discovery partnership

Algen Biotechnologies and AstraZeneca are entering into a multi-target research collaboration to advance AI-powered drug discovery in immunology.

October 17, 2025

Vol.51 No.38

Drugs & Targets

FDA approves durvalumab for muscle invasive bladder cancer

FDA approved AstraZeneca’s durvalumab (Imfinzi) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer.

April 04, 2025

Vol.51 No.13

Clinical Roundup

A post-treatment blood test could inform future cancer therapy decisions, study shows

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Imfinzi + chemo shows improved EFS and OS in muscle-invasive bladder cancer

Positive results from the NIAGARA phase III trial showed Imfinzi (durvalumab)in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key secondary endpoint of overall survival versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Follow-up data for Imfinzi + Imjudo shows OS benefit in unresectable HCC

Updated results from the HIMALAYA phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival benefit at five years for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.

September 20, 2024

Vol.50 No.35

Drugs & Targets

FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC

FDA granted priority review for Imfinzi (durvalumab), AstraZeneca’s supplemental Biologics License Application, based on the results from the positive ADRIATIC phase III trial in patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based concurrent chemoradiotherapy.

September 06, 2024

Vol.50 No.33

C2i Genomics, AstraZeneca to collaborate on MRD test for clinical R&D

YOU MAY BE INTERESTED IN

Algen Biotechnologies, AstraZeneca form AI drug discovery partnership

FDA approves durvalumab for muscle invasive bladder cancer

A post-treatment blood test could inform future cancer therapy decisions, study shows

Imfinzi + chemo shows improved EFS and OS in muscle-invasive bladder cancer

Follow-up data for Imfinzi + Imjudo shows OS benefit in unresectable HCC

FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC

Renew today!

Subscriber content

Never miss an issue!

Login